These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 26934663)

  • 21. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials.
    Stefanini GG; Byrne RA; Serruys PW; de Waha A; Meier B; Massberg S; Jüni P; Schömig A; Windecker S; Kastrati A
    Eur Heart J; 2012 May; 33(10):1214-22. PubMed ID: 22447805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of resolute zotarolimus-eluting stents compared with everolimus-eluting stents: a meta-analysis.
    Piccolo R; Stefanini GG; Franzone A; Spitzer E; Blöchlinger S; Heg D; Jüni P; Windecker S
    Circ Cardiovasc Interv; 2015 Apr; 8(4):. PubMed ID: 25858975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.
    Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Sabaté M; Smits PC; Kaiser C; D'Ascenzo F; Frati G; Mancone M; Genereux P; Stone GW
    J Am Coll Cardiol; 2014 Feb; 63(4):299-307. PubMed ID: 24211507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicenter randomized trial comparing amphilimus- with paclitaxel-eluting stents in de novo native coronary artery lesions.
    Carrié D; Berland J; Verheye S; Hauptmann KE; Vrolix M; Violini R; Dibie A; Berti S; Maupas E; Antoniucci D; Schofer J
    J Am Coll Cardiol; 2012 Apr; 59(15):1371-6. PubMed ID: 22284328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Everolimus-eluting versus sirolimus-eluting coronary stents in patients with and without diabetes mellitus.
    Kang SH; Park KH; Ahn HS; Park KW; Hong YJ; Koo BK; Jeong MH; Kim HS
    EuroIntervention; 2014 May; 10(1):74-82. PubMed ID: 24345385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zotarolimus- versus everolimus-eluting stents for unprotected left main coronary artery disease.
    Mehilli J; Richardt G; Valgimigli M; Schulz S; Singh A; Abdel-Wahab M; Tiroch K; Pache J; Hausleiter J; Byrne RA; Ott I; Ibrahim T; Fusaro M; Seyfarth M; Laugwitz KL; Massberg S; Kastrati A;
    J Am Coll Cardiol; 2013 Dec; 62(22):2075-82. PubMed ID: 23973699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes with various drug-eluting or bare metal stents in patients with ST-segment-elevation myocardial infarction: a mixed treatment comparison analysis of trial level data from 34 068 patient-years of follow-up from randomized trials.
    Bangalore S; Amoroso N; Fusaro M; Kumar S; Feit F
    Circ Cardiovasc Interv; 2013 Aug; 6(4):378-90. PubMed ID: 23922145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Second-versus first-generation "Limus"-eluting stents in diabetic patients with coronary artery disease: a randomized comparison in setting of ISAR-TEST-4 trial.
    Kufner S; Byrne RA; Mehilli J; Massberg S; Birkmeier KA; Schulz S; Pache J; Schömig A; Kastrati A
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):E769-76. PubMed ID: 23754254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical impact of second-generation everolimus-eluting stent compared with first-generation drug-eluting stents in diabetes mellitus patients: insights from a nationwide coronary intervention register.
    Kedhi E; Gomes ME; Lagerqvist B; Smith JG; Omerovic E; James S; Harnek J; Olivecrona GK
    JACC Cardiovasc Interv; 2012 Nov; 5(11):1141-9. PubMed ID: 23174638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meeting the Unmet - The Cre8 Polymer-free Drug-eluting Stents Technology: Proceedings of a satellite symposium held at EuroPCR on May 20th - 23rd 2014 in Paris.
    Mountfort K; Carrié D; Valgimigli M; Sardella G; Banai S; Romaguera R; Stella P
    Interv Cardiol; 2014 Aug; 9(3):184-189. PubMed ID: 29588800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: a randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III) Trial.
    Park DW; Kim YH; Song HG; Ahn JM; Kim WJ; Lee JY; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Seung KB; Yang TH; Lee SG; Lee JH; Seong IW; Cheong SS; Lee BK; Lee NH; Lee SW; Lee SW; Lee K; Kim HS; Jeon DS; Kim MK; Nah DY; Tahk SJ; Park SJ
    JACC Cardiovasc Interv; 2011 Oct; 4(10):1096-103. PubMed ID: 22017935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial.
    von Birgelen C; Sen H; Lam MK; Danse PW; Jessurun GA; Hautvast RW; van Houwelingen GK; Schramm AR; Gin RM; Louwerenburg JW; de Man FH; Stoel MG; Löwik MM; Linssen GC; Saïd SA; Nienhuis MB; Verhorst PM; Basalus MW; Doggen CJ; Tandjung K
    Lancet; 2014 Feb; 383(9915):413-23. PubMed ID: 24183564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
    Chen SL; Ye F; Zhang JJ; Zou JJ; Qian XS; Li F; Yang S; Ge Z; Shan SJ; Li XB; Xu T; Kan J; Lin L; Han YL
    Cardiovasc Ther; 2013 Aug; 31(4):193-200. PubMed ID: 22954234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Approach to coronary bifurcation lesions using the everolimus-eluting stent: comparison between a simple strategy and a complex strategy with T-stenting.
    Ruiz-Salmerón RJ; Valenzuela LF; Pérez I; Fuentes M; Rodríguez-Leiras S; Vizcaíno M; Carrascosa C; Marcos F
    Rev Esp Cardiol (Engl Ed); 2013 Aug; 66(8):636-43. PubMed ID: 24776332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of diabetes on the benefits from everolimus-eluting stent as compared to first-generation drug-eluting stent in patients with ST elevation myocardial infarction.
    De Luca G; Sauro R; Capasso M; Lanzillo T; Manganelli F; Carbone G; Lanni F; Pagliuca MR; Palmieri V; Serino V; Rosato G; Suryapranata H; Di Lorenzo E
    Diab Vasc Dis Res; 2015 Sep; 12(5):306-14. PubMed ID: 26150193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial.
    Harada Y; Colleran R; Kufner S; Giacoppo D; Rheude T; Michel J; Cassese S; Ibrahim T; Laugwitz KL; Kastrati A; Byrne RA;
    Cardiovasc Diabetol; 2016 Sep; 15(1):124. PubMed ID: 27586678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two-year follow-up of outcomes of second-generation everolimus-eluting stents versus first-generation drug-eluting stents for stenosis of saphenous vein grafts used as aortocoronary conduits.
    Kitabata H; Loh JP; Pendyala LK; Badr S; Dvir D; Barbash IM; Minha S; Torguson R; Chen F; Satler LF; Suddath WO; Kent KM; Pichard AD; Waksman R
    Am J Cardiol; 2013 Jul; 112(1):61-7. PubMed ID: 23561590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents: The RIBS IV Randomized Clinical Trial.
    Alfonso F; Pérez-Vizcayno MJ; Cárdenas A; García del Blanco B; García-Touchard A; López-Minguéz JR; Benedicto A; Masotti M; Zueco J; Iñiguez A; Velázquez M; Moreno R; Mainar V; Domínguez A; Pomar F; Melgares R; Rivero F; Jiménez-Quevedo P; Gonzalo N; Fernández C; Macaya C;
    J Am Coll Cardiol; 2015 Jul; 66(1):23-33. PubMed ID: 26139054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
    Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.